PPT-A phase 1 FIH study of AMG 701, an anti-BCMA

halflife extended HLE BiTE bispecific Tcell engager molecule in relapsed refractory multiple myeloma Simon J Harrison 1 Monique C Minnema 2 Hans C Lee 3 Andrew Spencer. . B. ar. c. ode . M. edication . A. dministration (. BCMA. ). Alyson . Kinley. Wright State University. What is BCMA?. A computerized system used by nurses to administer medications to . patients. via Federated . RFID Tags’ . Diversities. Lei Yang. Tsinghua University. Pai. Peng, Fan Dang, Xiang-Yang Li, . Yunhao. Liu . D. iversity. Fingerprinting genuineness. 04.. Outline. Overview. 02.. Fingerprinting tags. Dr. . Sengottuvel. . Viswanathan. Delhi University. Delhi. Epilepsy- recurrent seizures due to chronic underlying process. Incidence is 5 to 7 per 10,000 children .. 5 among 1,000 children have epilepsy .. Magnet Tours. Vision. Project-based and hands-on learning. High school credits in 7th and 8th grade . Exposure to pathways in B. iomedical . S. cience. Become college and career ready at an early age. Dr. . Sengottuvel. . Viswanathan. Delhi University. Delhi. Epilepsy- recurrent seizures due to chronic underlying process. Incidence is 5 to 7 per 10,000 children .. 5 among 1,000 children have epilepsy .. Frédéric Triebel, M.D., PhD. , Prima Biomed Ltd. Three groups of patients responding to anti-PD-1 . (IFN-.  signature). A- Inflamed responders – respond to anti-PD-1. B- Inflamed non-responders (some infiltrates in the tumor margins but no response). 2017-2018. Vision. Project-based and hands-on learning. High school credits in 7th and 8th grade . Exposure to pathways in Biomedical Science. Become college and career ready at an early age. A unique and accelerated curriculum . This program will include a discussion of . investigational agents not approved by the FDA for use in the United States. . IBD Background. Evolving Treatment Landscape in IBD. Limitations of Current IBD Therapies. Part 2. Resident and Fellows Lecture Series. A. pril 12, 2016. Elizabeth Garrett-Mayer, . PhD. Hollings Cancer . Center. . Current State of Phase II. Lots of changes in the past several years. Phase I . June 6, 2019. Adam D. Cohen, MD. Director, Myeloma Immunotherapy. Assistant. Professor, Medicine. Abramson Cancer Center. University of Pennsylvania. Outline. Background. Antibodies and antibody-drug conjugates. Chimeric Antigen Receptor . (CAR) T Cells in Advanced . Multiple Myeloma (MM). First-in-human Phase I study. N. = 12. . patients with advanced . relapsed/. refractory MM, ≥3 . prior . lines of therapy and . A. ccelerated, . D. ose escalated, . S. equential . C. hemo-r. a. diotherapy . in . N. on-Small Cell Lung Cancer. Rationale:. Lung cancer. is the most common cause of cancer mortality in the UK, and . BCMA, B-cell maturation antigen; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; GPC3, Glypican-3; HCC, hepatocellular carcinoma; HIV, human immunodeficiency . virus; IIT, investigator-initiated trial; NHL, non-Hodgkin lymphomas; MM, multiple myeloma; NSCLC, non small cell lung cancer; SCLC, small cell lung cancer; TCL, T-cell lymphoma. A series of learning points involving a case . of anti-e late sensitisation in . pregnancy, . suspected HDFN and . difficult component selection decision. Case Study Background. Patient NB . 40yr old antenatal patient.